伊立替康
体内
拓扑替康
治疗指标
连接器
化学
药理学
喜树碱
耐受性
癌症研究
拓扑异构酶
药品
医学
体外
癌症
化疗
生物化学
生物
内科学
不利影响
结直肠癌
生物技术
计算机科学
操作系统
作者
Floris Louis van Delft
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-07-01
卷期号:81 (13_Supplement): 1873-1873
被引量:1
标识
DOI:10.1158/1538-7445.am2021-1873
摘要
Abstract Camptothecins form a powerful class of chemotherapy drugs (e.g. irinotecan, topotecan, belotecan), based on their ability to inhibit topoisomerase I. Some camptothecins, such as DXd and SN-38, have also proven powerful payloads for antibody-drug conjugates (ADCs), as exemplified by the recent market approval of Enhertu® and Trodelvy®, respectively. We have reported earlier that the native glycan of monoclonal antibodies is a priviliged conjugation site for ADCs (GlycoConnect™)1, while the highly polar spacer technology (HydraSpace™)2 enables the conjugation of any cytotoxic payload, providing ADCs with significantly expanded therapeutic index (TI) versus mainstream ADC technologies. We here show that exatecan (DX-8951f), a clinically validated and potent campothecin, is readily combined with HydraSpace™ technology to provide linker-payload (SYNtecan E™). Homogeneous and stable GlycoConnect™ADCs were generated from trastuzumab and SYNtecan E™ and compared head-to-head with DXd or SN-38payload, as well as deruxtecan, the linker-payload applied in Enhertu®. Complete tumor regression was observed in a mouse xenograft study (BT-474) after a single dose, while safety studies in mouse corroborated the high tolerability of SYNtecan E™ ADCs. Taken together, these studies demonstrate the potential of SYNtecan E™ for application in stable and site-specific ADCs with excellent therapeutic index. 1 van Geel et al. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of NativemAbs Provides Homogeneous and Highly Efficacious Antibody−Drug Conjugates. Bioconj. Chem. 2015, 26, 2233-2242. 2 Verkade et al. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates. Antibodies 2018, 7, 12, doi:10.3390/antib7010012. Citation Format: Floris van Delft. GlycoConnect™ ADCs based on topoisomerase 1 inhibitor exatecan (SYNtecan E™) show excellent in vivo efficacy and tolerability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1873.
科研通智能强力驱动
Strongly Powered by AbleSci AI